Clinical Trial Update: The AIM Study: Assessing the Impact of Margin Reduction

View source ↗

Summary

The AIM Study, sponsored by Varian (a Siemens Healthineers company), has completed and reports results on the impact of margin reduction in prostate cancer trea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Snippet

Sponsor: Varian, a Siemens Healthineers Company | Conditions: Prostate Cancer | Status: COMPLETED